Eagle Pharmaceuticals Inc. (EGRX)
$0.93
$0.00 (0.00%)As on 28-Aug-2026 09:30EDT
Market cap
$3 Mln
Revenue (TTM)
$258 Mln
P/E Ratio
1
P/B Ratio
0.2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$16 Mln
-
ROE
0 %
-
ROCE
-- %
-
Industry P/E
37.32
-
EV/EBITDA
1.7
-
Debt to Equity
0.2
-
Book Value
$--
-
EPS
$1.2
-
Face value
--
-
Shares outstanding
13,157,553
10 Years Aggregate
CFO
$319.47 Mln
EBITDA
$282.48 Mln
Net Profit
$197.16 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Eagle Pharmaceuticals (EGRX)
| 172.1 | 150.0 | 140.3 | -71.0 | -62.1 | -54.5 | -34.1 |
|
BSE Sensex*
| -9.1 | -1.2 | 2.9 | -3.6 | 5.7 | 6.2 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
Eagle Pharmaceuticals (EGRX)
| -82.1 | -42.6 | 9.3 | -22.5 | 49.1 | -24.5 | -32.7 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Eagle Pharmaceuticals (EGRX)
|
0.9 | 3.3 | 257.6 | 15.6 | 13.7 | -83.4 | 1 | 0.2 |
| 17.5 | 6,109.1 | 3,117.6 | 157.4 | 14.7 | -- | 37.3 | 190.1 | |
| 41.0 | 5,252.7 | 1,105.3 | 133.3 | 16.2 | 32.7 | 38.3 | 12.7 | |
| 198.5 | 10,424.8 | 776.6 | -191.6 | -17.6 | -223.4 | -- | 129.6 | |
| 76.6 | 14,974.8 | 691.8 | -696.2 | -89.1 | -- | -- | 123.7 | |
| 113.4 | 12,310.3 | 830.8 | 54.9 | 3.2 | 8.1 | 264.8 | 17.9 | |
| 24.0 | 11,971.8 | 5,020.0 | -199.0 | 1.6 | -3 | -- | 1.8 | |
| 284.1 | 5,591.7 | 290.5 | 197.2 | 82.5 | 19.9 | 28.9 | 5.9 | |
| 68.2 | 6,058.9 | 450.9 | 138.6 | 39.1 | 115.6 | 50.1 | 32.1 | |
| 139.0 | 8,865.6 | 431.8 | -136.7 | -30.8 | -30.3 | -- | 21.5 |
Shareholding Pattern
View DetailsAbout Eagle Pharmaceuticals (EGRX)
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The... company's product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. It also produces PEMFEXY, a ready-to-dilute liquid form of pemetrexed injection, indicated in combination with cisplatin for the initial treatment of patients with malignant pleural mesothelioma and non-small cell lung cancer; BARHEMSYS, a selective dopamine-2 (D2) and dopamine-3 (D3) receptor antagonist indicated in adults for prevention of postoperative nausea and vomiting (PONV); BYFAVO, a benzodiazepine indicated for the induction and maintenance of procedural sedation in adults. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an anti-toxin agent in Phase 2 development for the treatment of severe pneumonia in combination with traditional antibacterial drugs; ENA-001 developed by Enalare, an agnostic respiratory stimulant for respiratory depression; EA-114, novel and proprietary formulation of fulvestrant developed for hormone-receptor-positive (HR+) metastatic breast cancer. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat cancer. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey. Read more
-
Interim Principal Executive Officer & Executive Chairman of the Board
Mr. Michael Graves
-
Interim Principal Executive Officer & Executive Chairman of the Board
Mr. Michael Graves
-
Headquarters
Woodcliff Lake, NJ
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Eagle Pharmaceuticals (EGRX)
What is the current share price of Eagle Pharmaceuticals Inc (EGRX) Today?
The share price of Eagle Pharmaceuticals Inc (EGRX) is $0.93 (NASDAQ) as of 28-Aug-2026 09:30 EDT. Eagle Pharmaceuticals Inc (EGRX) has given a return of -62.07% in the last 3 years.
What is the current PB & PE ratio of Eagle Pharmaceuticals Inc (EGRX)?
The P/E ratio of Eagle Pharmaceuticals Inc (EGRX) is 1.00 times as on 28-Aug-2026, a 97 discount to its peers’ median range of 37.32 times.
The P/B ratio of Eagle Pharmaceuticals Inc (EGRX) is 0.16 times as on 28-Aug-2026, a 98 discount to its peers’ median range of 7.75 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2022 |
10.76 |
1.64 |
2021 |
-76.12 |
3.72 |
2020 |
53.49 |
3.45 |
2019 |
59.27 |
4.74 |
2018 |
18.55 |
3.68 |
What is the 52 Week High and Low of Eagle Pharmaceuticals Inc (EGRX)?
The 52-week high and low of Eagle Pharmaceuticals Inc (EGRX) are Rs 3.37 and Rs 0.00 as of 01-Sep-2026.
What is the market cap of Eagle Pharmaceuticals Inc (EGRX)?
Eagle Pharmaceuticals Inc (EGRX) has a market capitalisation of $ 3 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Eagle Pharmaceuticals Inc (EGRX)?
Before investing in Eagle Pharmaceuticals Inc (EGRX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.